Cargando…

Unique proteome signature of post-chemotherapy ovarian cancer ascites-derived tumor cells

Eighty % of ovarian cancer patients diagnosed at an advanced-stage have complete remission after initial surgery and chemotherapy. However, most patients die within <5 years due to episodes of recurrences resulting from the growth of residual chemoresistant cells. In an effort to identify mechani...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ahmed, Nuzhat, Greening, David, Samardzija, Chantel, Escalona, Ruth M., Chen, Maoshan, Findlay, Jock K., Kannourakis, George
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4965858/ https://www.ncbi.nlm.nih.gov/pubmed/27470985 http://dx.doi.org/10.1038/srep30061

Ejemplares similares

Knockdown of stem cell regulator Oct4A in ovarian cancer reveals cellular reprogramming associated with key regulators of cytoskeleton-extracellular matrix remodelling
por: Samardzija, Chantel, et al.
Publicado: (2017)

Expression of TIMPs and MMPs in Ovarian Tumors, Ascites, Ascites-Derived Cells, and Cancer Cell Lines: Characteristic Modulatory Response Before and After Chemotherapy Treatment
por: Escalona, Ruth M., et al.
Publicado: (2022)

Coalition of Oct4A and β1 integrins in facilitating metastasis in ovarian cancer
por: Samardzija, Chantel, et al.
Publicado: (2016)

The Many Facets of Metzincins and Their Endogenous Inhibitors: Perspectives on Ovarian Cancer Progression
por: Escalona, Ruth M., et al.
Publicado: (2018)

TIMP-2 regulates proliferation, invasion and STAT3-mediated cancer stem cell-dependent chemoresistance in ovarian cancer cells
por: Escalona, Ruth M., et al.
Publicado: (2020)

Knock down of TIMP-2 by siRNA and CRISPR/Cas9 mediates diverse cellular reprogramming of metastasis and chemosensitivity in ovarian cancer
por: Escalona, Ruth M., et al.
Publicado: (2022)

Attributes of Oct4 in stem cell biology: perspectives on cancer stem cells of the ovary
por: Samardzija, Chantel, et al.
Publicado: (2012)

A critical role of Oct4A in mediating metastasis and disease-free survival in a mouse model of ovarian cancer
por: Samardzija, Chantel, et al.
Publicado: (2015)

Paclitaxel-Induced Src Activation Is Inhibited by Dasatinib Treatment, Independently of Cancer Stem Cell Properties, in a Mouse Model of Ovarian Cancer
por: Kadife, Elif, et al.
Publicado: (2019)

Momelotinib decreased cancer stem cell associated tumor burden and prolonged disease-free remission period in a mouse model of human ovarian cancer
por: Chan, Emily, et al.
Publicado: (2018)

Neuronal transcription factor Brn-3a(l) is over expressed in high-grade ovarian carcinomas and tumor cells from ascites of patients with advanced-stage ovarian cancer
por: Ahmed, Nuzhat, et al.
Publicado: (2010)

Isolation and Characterization of Tumor Cells from the Ascites of Ovarian Cancer Patients: Molecular Phenotype of Chemoresistant Ovarian Tumors
por: Latifi, Ardian, et al.
Publicado: (2012)

Targeted Disruption of the JAK2/STAT3 Pathway in Combination with Systemic Administration of Paclitaxel Inhibits the Priming of Ovarian Cancer Stem Cells Leading to a Reduced Tumor Burden
por: Abubaker, Khalid, et al.
Publicado: (2014)

The attributes of plakins in cancer and disease: perspectives on ovarian cancer progression, chemoresistance and recurrence
por: Wesley, Tamsin, et al.
Publicado: (2021)

In Vitro and In Silico Analysis of Epithelial-Mesenchymal Transition and Cancer Stemness as Prognostic Markers of Clear Cell Renal Cell Carcinoma
por: Sharma, Revati, et al.
Publicado: (2023)

Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden
por: Abubaker, Khalid, et al.
Publicado: (2013)

Getting to Know Ovarian Cancer Ascites: Opportunities for Targeted Therapy-Based Translational Research
por: Ahmed, Nuzhat, et al.
Publicado: (2013)

Ovarian Cancer, Cancer Stem Cells and Current Treatment Strategies: A Potential Role of Magmas in the Current Treatment Methods
por: Ahmed, Nuzhat, et al.
Publicado: (2020)

Precision Medicine: An Optimal Approach to Patient Care in Renal Cell Carcinoma
por: Sharma, Revati, et al.
Publicado: (2022)

Loss of PUMA protects the ovarian reserve during DNA-damaging chemotherapy and preserves fertility
por: Nguyen, Quynh-Nhu, et al.
Publicado: (2018)

Chemotherapy sensitivity testing on ovarian cancer cells isolated from malignant ascites
por: den Ouden, Judith E., et al.
Publicado: (2020)

Unique Proteomic Signatures Distinguish Macrophages and Dendritic Cells
por: Becker, Lev, et al.
Publicado: (2012)

Proteomics reveals unique plasma signatures in constitutional thinness
por: Cominetti, Ornella, et al.
Publicado: (2022)

Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden
por: Abubaker, Khalid, et al.
Publicado: (2014)

Post-Malarial Ascites
por: Young, John C.
Publicado: (1909)

The Development of an Angiogenic Protein “Signature” in Ovarian Cancer Ascites as a Tool for Biologic and Prognostic Profiling
por: Trachana, Sofia-Paraskevi, et al.
Publicado: (2016)

Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial–mesenchymal transition interlinked with reprogrammed metabolism
por: Leung, Dilys, et al.
Publicado: (2022)

Conversion therapy of gastric cancer with massive malignant ascites and ovarian metastases by systemic and intraperitoneal chemotherapy
por: Kondo, Tomohiro, et al.
Publicado: (2016)

Ascitic complement system in ovarian cancer
por: Bjørge, L, et al.
Publicado: (2005)

The bright side of ascites in ovarian cancer
por: Cohen, Marie, et al.
Publicado: (2014)

Ascites Volumes and the Ovarian Cancer Microenvironment
por: Penet, Marie-France, et al.
Publicado: (2018)

Effect of ovarian cancer ascites on SKOV-3 cells proteome: new proteins associated with aggressive phenotype in epithelial ovarian cancer
por: Toledo-Leyva, Alfredo, et al.
Publicado: (2018)

Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo
por: Greening, David W., et al.
Publicado: (2016)

Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma
por: Sharma, Revati, et al.
Publicado: (2021)

The ovarian reserve is depleted during puberty in a hormonally driven process dependent on the pro-apoptotic protein BMF
por: Liew, Seng H, et al.
Publicado: (2017)

Disaggregation and invasion of ovarian carcinoma ascites spheroids
por: Burleson, Kathryn M, et al.
Publicado: (2006)

Deciphering the ovarian cancer ascites fluid peptidome
por: Bery, Anand, et al.
Publicado: (2014)

Chlamydia Peritonitis and Ascites Mimicking Ovarian Cancer
por: Gojayev, Anar, et al.
Publicado: (2016)

Immune Tumor Microenvironment in Ovarian Cancer Ascites
por: Almeida-Nunes, Diana Luísa, et al.
Publicado: (2022)

Oncolytic adenovirus inhibits malignant ascites of advanced ovarian cancer by reprogramming the ascitic immune microenvironment
por: Shi, Gang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ke56tmhqd66g6gdc9mn63k7hqd